MetaCap

NewcelX Ltd. (NCEL)

NASDAQ: NCELHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.54-0.15 (-5.58%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NCEL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$14.67M
52-week range
1.83 – 5.12
Day range
2.45 – 2.63
Volume / Avg
5.61K / 13.34K
Beta
—

52-week range

$1.83$5.12

NCEL stock today

NewcelX (NCEL) closed at $2.54 on Nov 20, down 5.58% (-$0.15), versus the S&P 500's 3.70% decline. Trading was light, with 5.61K shares changing hands, about 42% of the average daily volume. At this level, NCEL sits in the middle of its 52-week range of $1.83 to $5.12: 50.4% below the high, set on Apr 24, 2026 and 38.8% above the low.

NCEL is up 33.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 22.3%. NewcelX trades at 4.9x its trailing twelve-month earnings per share of $0.52.

Summary generated from market data by MetaCap's automated system. Methodology

About NewcelX

Company profile

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Ronen Twito CPA
Headquarters
Kloten
Employees
9
IPO year
2021

Financial highlights

Full financials

NewcelX reported a net loss of $8.3 million, compared with a loss of $7.2 million a year earlier. Diluted earnings per share came in at $2.16, down from $2.43.

NewcelX annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-8.30M$-7.20M$-3.33M$-16.50M$-11.95M
EPS (diluted)$2.16$2.43$1.13$-33.52$-1.00

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$23.00+805.51%

  • Strong buy 1
  • Buy 0
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

NCEL news

All NCEL news

NewcelX peers

Health Care sector
NCEL peer companies
CompanyPrice% ChgMarket capCompare
CNTXContext Therapeutics Inc.0.16-5.10%$14.70Mvs NCEL
CELUCelularity Inc. Class A0.463-1.05%$15.02Mvs NCEL
CTXRCitius Pharmaceuticals Inc.0.5085+2.27%$13.96Mvs NCEL
BYSIBeyondSpring Inc.0.33-24.49%$13.66Mvs NCEL
ACTUActuate Therapeutics Inc.0.2253+5.38%$13.60Mvs NCEL
QNRXQuoin Pharmaceuticals Ltd. ADR3.28-2.35%$15.76Mvs NCEL
PBMPsyence Biomedical Ltd.2.97+3.85%$15.80Mvs NCEL
ATOSAtossa Therapeutics Inc.1.60-8.86%$15.92Mvs NCEL

Indexes, lists and sector

NewcelX stock FAQ

What is NewcelX's stock price today?

NCEL last traded at $2.54 as of Nov 20, 4:00 PM EST, down 5.58% on the day. Prices are delayed at least 15 minutes.

Does NewcelX pay a dividend?

No. NewcelX does not currently pay a regular cash dividend.

What is NCEL's P/E ratio?

NCEL trades at a trailing P/E ratio of 4.88.

Who is NewcelX's CEO?

Mr. Ronen Twito CPA is the chief executive officer of NewcelX Ltd., which has about 9 employees.

Has NCEL ever split its stock?

Yes. The most recent NCEL stock split was a 1-for-10 split on Oct 31, 2025, one of 2 splits on record.

What is the NCEL 52-week high?

The 52-week high for NCEL is $5.12 and the 52-week low is $1.83. The stock is currently 50.4% below its high.

Compare NCEL